Pharmacogenetics of antidepressant response::A polygenic approach by García-González, Judit et al.
                          García-González, J., Tansey, K. E., Hauser, J., Henigsberg, N., Maier, W.,
Mors, O., ... Fabbri, C. (2017). Pharmacogenetics of antidepressant response:
A polygenic approach. Progress in Neuro-Psychopharmacology and
Biological Psychiatry, 75, 128-134.
https://doi.org/10.1016/j.pnpbp.2017.01.011
Peer reviewed version
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.pnpbp.2017.01.011
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S0278584616304389?via%3Dihub . Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Pharmacogenetics of antidepressant response: a polygenic approach
Judit García-González1, Katherine E. Tansey2, Joanna Hauser3, Neven Henigsberg4, 
Wolfgang Maier5, Ole Mors6,7, Anna Placentino8, Marcella Rietschel9, Daniel Souery10, Tina 
Žagar11, Piotr M. Czerski12, Borut Jerman11,13, Henriette N. Buttenschøn14, Thomas G. 
Schulze15, Astrid Zobel5, Anne Farmer1, Katherine J. Aitchison16, Ian Craig1, Peter 
McGuffin1, Michel Giupponi17, Nader Perroud18, Guido Bondolfi19, David Evans20, Michael 
O'Donovan21, Tim J. Peters22, Jens R. Wendland23, Glyn Lewis24, Shitij Kapur1, Roy Perlis25, 
Volker Arolt26, Katharina Domschke27, Major Depressive Disorder Working Group of  the 
Psychiatric Genomic Consortium28, Gerome Breen1, Charles Curtis1, Lee Sang-Hyuk1, Carol 
Kan1, Stephen Newhouse1, Hamel Patel1, Bernhard T. Baune29, Rudolf Uher30, Cathryn M. 
Lewis 1*, Chiara Fabbri1,31*
* These two authors jointly supervised the study
1 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, United 
Kingdom
2 College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
3 Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of 
Medical Sciences, Poznan, Poland
4 Croatian Institute for Brain Research, Medical School, University of Zagreb, Zagreb, 
Croatia
5 Department of Psychiatry, University of Bonn, Bonn, Germany
6 Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark
7 The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH),
Aarhus, Denmark
8 Biological Psychiatry Unit and Dual Diagnosis Ward, Istituto Di Ricovero e Cura a 
Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy
9 Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, 
Mannheim, Germany
10 Laboratoire de Psychologie Médicale, Université Libre de Bruxelles and Psy Pluriel—
Centre Européen de Psychologie Médicale, Brussels, Belgium
11 Institute of Public Health of the Republic of Slovenia, Ljubljana, Slovenia
12 Laboratory of Psychiatric Genetics, Poznan University of Medical Sciences, Poland
13 Department of Molecular and Biomedical Sciences, Jozef Stefan Institute, Ljubljana, 
Slovenia
214 Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, 
Risskov, Denmark
15 Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, 
Mannheim, Germany
16 Department of Psychiatry, University of Alberta, Edmonton, AB, Canada
17 Department of Genetic Medicine and Laboratories, University Hospitals of Geneva, 
Geneva, Switzerland
18 Department of Psychiatry, University of Geneva, Geneva, Switzerland
19 Center of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Medicines 
Research Centre, Verona, Italy
20 Medical Research Council CAiTE Centre, School of Social and Community Medicine, 
University of Bristol, Bristol, United Kingdom
21 Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, 
Department of Psychological Medicine and Neurology, School of Medicine, Cardiff 
University, Cardiff, United Kingdom
22 School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
23 Pharma Research and Early Development, F. Hoffmann–La Roche, Basel, Switzerland
24 Division of Psychiatry, University College London, London, UK 
25 Department of Psychiatry, Center for Experimental Drugs and Diagnostics, Massachusetts 
General Hospital, Boston, USA
26 Department of Psychiatry, University of Münster, Münster, Germany
27 Department of Psychiatry Psychosomatics and Psychotherapy , University of Wuerzburg , 
Wuerzburg , Germany
28 Full list of Consortium members is given in Supplementary Materials S1
29 Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, Australia
30 Department of Psychiatry, Dalhousie University, Halifax, Canada
31 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 
Italy
Corresponding author: 
Professor Cathryn Lewis, PhD
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & 
Neuroscience
De Crespigny Park, London SE5 8AF
Tel: +44-20-7848-0661
3Email: Cathryn.lewis@kcl.ac.uk
4Abstract 
Background Major depressive disorder (MDD) has a high personal and socio-economic 
burden and more than 60% of patients fail to achieve remission with the first antidepressant. 
The biological mechanisms behind antidepressant response are only partially known but 
genetic factors play a relevant role. A combined predictor across genetic variants may be 
useful to investigate this complex trait. 
Methods Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) 
antidepressant efficacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and 
tested whether these predicted symptom improvement or remission from the GENDEP study 
(n=736) to the STAR*D study (n=1409) and vice-versa, including the whole sample or only 
patients treated with escitalopram or citalopram. Using summary statistics from Psychiatric 
Genomics Consortium for MDD and schizophrenia, we tested whether PRS from these 
disorders predicted symptom improvement in GENDEP, STAR*D, and five further studies 
(n=3756).  
Results: No significant prediction of antidepressant efficacy was obtained from PRS in 
GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence 
of overlap in the genetics of antidepressant response with either MDD or schizophrenia, 
either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the 
results.  
Discussion: We identified no significant predictive effect using PRS between 
pharmacogenetic studies. The genetic liability to MDD or schizophrenia did not predict 
response to antidepressants, suggesting differences between the genetic component of 
depression and treatment response. Larger or more homogeneous studies will be necessary to 
obtain a polygenic predictor of antidepressant response.
Keywords: antidepressant; pharmacogenomics; polygenic risk scores; major depressive 
disorder; schizophrenia
5Introduction 
Major depressive disorder (MDD) is a common mental disorder characterized by sadness, 
anhedonia, guilt, feelings of low self-worth, poor concentration, disturbed appetite and sleep 
and suicidal thoughts (World Health Organization, 1993; American Psychiatric Association, 
2013). Its heavy socio-economic and individual burden makes it a global concern: lifetime 
prevalence of MDD ranges from 10% to 15% and MDD is one of the top ten causes of years 
lived with disability (YLDs) worldwide (The WHO World Mental Health Survey 
Consortium, 2004; Global Burden of Disease Study 2013 Collaborators, 2015). 
Antidepressant drugs are the first-line treatment for MDD, with more than 30 antidepressant 
drugs available (Fabbri et al., 2016). Responses vary widely across individuals: one third of 
patients show complete remission after the first drug prescribed, one third improves after a 
change of treatment or augmentation, and one third fail to respond after two different 
antidepressants prescribed (Trivedi et al., 2006; Souery et al., 2011). For each patient, the 
most effective treatment can only be identified by trial and error - a lengthy process which 
delays recovery and leads to poorer clinical outcomes (Steimer et al., 2001). The ability to 
identify the most effective drugs for each patient or to predict treatment resistance would be a 
turning point in MDD treatment, enabling personalized prescribing. However, no predictor of 
antidepressant response is currently available; clinical characteristics are weak predictors of 
improvement in depressive symptoms, and no established biomarkers or genetic signatures 
exist for antidepressant response.
Genome-wide association studies (GWAS) to identify single nucleotide polymorphisms 
(SNPs) associated with antidepressant response have provided tentative hints, but most 
associations have been inconclusive and are unreplicated (Myung et al., 2015; Sasayama et 
al., 2013; Biernacka et al., 2015; GENDEP Investigators, MARS Investigators and STAR*D 
Investigators, 2013; Uher et al., 2010; Trivedi et al., 2006; Ising et al., 2009). These 
disappointing findings may be ascribed to several features of pharmacogenetic studies: 
limited sample size, heterogeneity between studies in design, drug, and assessment of 
outcome. Given the challenges of accruing sufficiently strong evidence to confirm association 
of a single SNP with antidepressant response, an alternative approach is to construct a single 
summary genetic variable representing genome-wide information which can be used for 
prediction. 
Polygenic risk scores (PRS) capture in a single variable the additive effect of SNP alleles 
across the genome (Dudbridge, 2013). In contrast to GWAS analysis, where a single SNP 
must reach stringent significance levels, PRS are constructed from multiple SNPs with lower 
evidence of association, with the assumption that genetic markers that do not meet the 
genome-wide significance threshold might have good predictive power when they are 
considered collectively.
In this study we test whether polygenic risk scores can provide prediction of response to anti-
depressants, building PRS directly from clinical trials of antidepressant response (STAR*D, 
GENDEP) (Garriock et al., 2010; Uher et al., 2010), and secondly testing the hypothesis of 
whether genetic liability to the psychiatric disorders of MDD and schizophrenia contributes 
6to variation in antidepressant response. Indeed an overlap between the genetics of MDD and 
antidepressant response has been hypothesized, but MDD also shares susceptibility genetic 
factors with schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2013), suggesting a possible overlap between the genetics of schizophrenia and 
antidepressant response. We analyse two large pharmacogenetic trials (GENDEP, STAR*D) 
and expand our study to other studies of antidepressant response, giving a substantial sample 
size in which to develop and test predictors of treatment response.
Materials and Methods 
Pharmacogenetic studies 
Seven pharmacogenetic studies were included, all similar in their fundamental features: (1) 
participants were treatment-seeking individuals diagnosed with MDD based on DSM-
IV/ICD-10 criteria (World Health Organization, 1993; American Psychiatric Association, 
2013), with other psychiatric diagnoses excluded (schizophrenia spectrum disorders, bipolar 
disorders, current alcohol or drug dependence). For each study participant, prospective data 
on outcome of antidepressant treatment were recorded according to standard and comparable 
scales. Missing end-point measurements were imputed using the best unbiased estimate from 
a mixed-effect linear regression model, with fixed linear and quadratic effects of time and 
random effects of individual and centre of recruitment (for multi-centric studies) according to 
previous studies (Tansey et al., 2012; Uher et al., 2010). Patients were included in the 
analyses only if baseline assessment and at least one post-baseline assessment were available. 
The GENDEP and STAR*D studies formed our primary studies for discovery and testing 
variants specific to antidepressant response. For testing the hypothesis that genetic liability 
for MDD and schizophrenia predicts antidepressant response, we included four further trials 
from the NEWMEDS consortium (GENPOD, GODS, GSK, Pfizer) (Tansey et al., 2012) and 
a newly genotyped naturalistic study from the University of Muenster (Baune et al., 2008, 
2010). All studies were approved by local ethics boards of participating centres, and all 
participants provided written informed consent after the study procedures were explained and 
prior to sample collection. Detailed information for each sample are given in Table 1 and 
Supplementary Methods.
Outcome measures 
Two phenotypes were investigated at the end-point of each study, a continuous measure of 
improvement, calculated as the percentage change in symptom score, and symptom remission 
(Table 1). Percentage change was preferred to absolute change because it is less correlated 
with initial severity, relatively independent of the scale, and closely reflects clinician’s 
impression of improvement (Uher et al., 2009; Lane, 2008; Mallinckrodt, Clark and David, 
2001). Remission was defined as a score below a consensus cut-off that corresponds to 
absence of depression for each scale (Hamilton, 1967; Montgomery and Asberg, 1979; Beck 
et al., 1961). For GENDEP, remission was defined using HAMD-17, since there was stronger 
consensus about the threshold to identify remission on this scale compared to MADRS (Uher 
7et al., 2008). Remission has lower power to detect an effect than a continuous measure 
(Streiner, 2002) but it may be associated with MDD prognosis (Gaynes et al., 2009). 
Psychiatric Genomics Consortium summary statistics
Genome-wide summary statistics for large meta-analysis from the Psychiatric Genomics 
Consortium (PGC) were used to construct PRS for MDD and schizophrenia for each 
participant in the pharmacogenomic studies.  Summary statistics for schizophrenia were 
downloaded from pgc.unc.edu (36,989 schizophrenia cases, 113,075 controls) (Ripke et al., 
2014). MDD summary statistics were from the latest PGC MDD meta-analysis comprising 
51,865 MDD cases and 112,200 controls (unpublished data).
Statistical analysis 
Individual-level genotypes were available for all pharmacogenetic studies. GENDEP and 
STAR*D were imputed using genotype data from genome-wide and exome arrays capturing 
both common and rare variation (Table 1; Supplementary Methods). The Muenster study was 
imputed from Infinium PsychArray-24, and phenotype and genotype data from studies in the 
NEWMEDS consortium (GENPOD, Pfizer,GSK, GODS) were used as previously reported 
(Tansey et al., 2012). All these studies were imputed using Minimac3 and the Haplotype 
Reference Consortium (HRC version 1) as reference panel. In STAR*D and GENDEP, tests 
of SNP association were performed using linear regression (for percentage change in 
symptom score) and logistic regression (remission) using PLINK (Purcell et al., 2007). Each 
model included covariates of ancestry-informative principal components, age, baseline 
severity of depression and ascertainment centre (for multi-centre studies of STAR*D, 
GENDEP and Pfizer).  
GWAS summary data from GENDEP, STAR*D, PGC-SCZ, and PGC-MDD were used as 
discovery studies. A schematic representation of study design is provided in Figure 1. SNPs 
were clumped by linkage disequilibrium (LD) and p-value: SNP with the smallest p-value 
within a 250 Kb window were retained, and all SNPs in LD (r2 > 0.1) with the retained SNP 
were excluded. When PGC-MDD was used as discovery study, markers with allele frequency 
diﬀerence of over 0.15 between discovery and test data sets were excluded to ensure 
comparability given the diﬀerent genotyping chips and imputation reference panels used. 
PRS were constructed using the software PRSice v.1.25 (Euesden, Lewis and O’Reilly, 
2015). PRS were calculated as the sum of associated alleles, weighted by eﬀect sizes, for 
SNPs with p-values less than pre-defined threshold PT. Nine p-value thresholds of PT < 
(0.0001, 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1) were used with all pruned SNPs included in the 
final threshold PT=1. Symptom improvement and remission outcomes were regressed on 
polygenic scores, adjusting for the covariates as used in the GWAS analyses, and compared 
to a model including only covariates. The proportion of phenotypic variance explained by 
PRS was assessed by R2 (for improvement) or Nagelkerke’s R2 (for remission). To decrease 
pharmacological heterogeneity across samples and to increase power, analyses were repeated 
stratifying by antidepressant, including only studies using escitalopram and citalopram 
(STAR*D, GSK, 417 GENDEP participants, 242 GENPOD participants and 121 Muenster 
participants).
8Prediction of improvement from MDD and schizophrenia was implemented separately in 
each pharmacogenetic study, then a fixed effects meta-analysis was performed to combine 
results across studies at each PT.  
A Bonferroni correction was applied to account for multiple testing. We estimated p=0.01 as 
an approximate correction for correlation between PRS at 9 PT values, and then corrected 
further for four independent hypotheses, giving a required significance level of p=0.0025.  
Power calculation 
Power calculations for the polygenic analysis were performed using the R package 
AVENGEME (Palla and Dudbridge, 2015), at each PT. Models assumed SNP heritability of 
0.21 for MDD (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013), 
0.42 for response to antidepressants (Tansey et al., 2013) and 0.33 for schizophrenia (Ripke 
et al., 2013a). Lifetime prevalences used were 16.2% for MDD (Kessler et al., 2003), and 
0.87% for schizophrenia (Perälä et al., 2007). The models used for power calculation 
assumed that the markers are independent and 5% of SNPs have an eﬀect in the training 
phenotype. For cross-trait polygenic analysis (MDD, schizophrenia and antidepressant 
response), two hypothetical scenarios were tested, comparing change in prediction accuracy 
when covariance between genetic eﬀects in the training and target samples were 25% or 
50%.
With GENDEP or STAR*D as discovery sample, the power to detect the genetic contribution 
of response to antidepressants was limited (12% for improvement, 8% for remission).  Using 
PGC MDD and PGC SCZ as discovery had higher power.  Assuming a covariance of 25% 
between SCZ and improvement in depression symptoms gave >90% power in the combined 
pharmacogenetic samples. A covariance of 50% between MDD and improvement in 
depression symptoms had 90% power to detect an effect in the combined pharmacogenetic 
sample, but only power of 37% with 25% covariance.    
9Results 
Firstly, we tested whether PRS predict improvement and remission in depression symptoms 
after twelve weeks of antidepressant treatment, using GENDEP and STAR*D. Each study 
was used as discovery and then as target study, testing the PRS constructed from STAR*D 
GWAS results in GENDEP, and vice-versa.  No significant prediction of treatment response 
was attained for improvement or for remission in the whole sample (Supplementary Figure 1) 
or restricting the analysis to citalopram/escitalopram (Supplementary Figure 2) treated 
patients (Table 2). The lowest p-value of p=0.023, using the GENDEP remission GWAS to 
predict remission in STAR*D, did not reach the required Bonferroni correction of 0.0025.  
Secondly, we investigated whether genetic liability to MDD or schizophrenia predicted 
improvement in depressive symptoms, using meta-analyses from the Psychiatric Genomics 
Consortium (PGC) as discovery samples. Seven pharmacogenetic studies (including 
GENDEP and STAR*D) were used as independent target samples (3746 participants). Meta-
analysis across studies (whole sample or citalopram/escitalopram treated patients) showed no 
predictive ability of genetic liability for MDD or for schizophrenia (Figure 2), with the most 
significant result being for schizophrenia PRS at PT<0.0001 (p=0.077). Across all PT, PRS for 
MDD showed p-values > 0.1 for the prediction of symptom improvement and regression 
coefficients explained less than 3% of the variance in symptom improvement.  Results by-
study at all PT values are given in Supplementary Tables 1-2.
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Discussion 
In this study, we assessed whether the outcomes of antidepressant treatment may be predicted 
by PRS for (a) improvement and remission from an independent sample, (b) genetic liability 
to MDD, and (c) genetic liability to schizophrenia.  Using each of the two largest available 
pharmacogenetic samples on antidepressant response (GENDEP and STAR*D) as baseline 
studies failed to predict antidepressant response in the other study. A previous study 
(GENDEP Investigators, MARS Investigators and STAR*D Investigators, 2013) found a 
small predicting ability of a PRS calculated in a meta-analysis of GENDEP-MARS studies in 
STAR*D, accounting for about 1.2% of the variance in outcomes in STAR*D.  The present 
study was performed using individual datasets as discovery samples but increasing the 
number of genetic variants from ~ 1.2 million to ~ 7 million.  PRS built from well-powered 
PGC studies for MDD and schizophrenia did not predict symptom improvement, either in 
individual pharmacogenetic studies, or in a meta-analysis. A previous analysis of PRS for 
bipolar disorder did not predict antidepressant response in STAR*D and the NEWMEDS 
studies, so this analysis was not repeated here (Tansey et al., 2014). 
This study represents the largest investigation of the PRS for antidepressant response to date, 
including the majority of currently available pharmacogenetic data on antidepressant 
response in MDD (3,746 participants from 7 studies). Both PGC discovery studies were well 
powered. The PGC schizophrenia study identified a genetic component accounting for 
approximately 7% of the liability to schizophrenia. MDD shares susceptibility genetic factors 
with schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), 
suggesting a possible overlap between the genetics of schizophrenia and antidepressant 
response. The unpublished PGC MDD meta-analysis has a substantially increased sample 
size from the previous study (Ripke et al., 2013b) as well as from the recent MDD GWAS 
from 23andme (Hyde et al., 2016). MDD PRS comparable to the ones we calculated could 
not be constructed from the 23andme study since only SNPs with p<10-5 are publicly 
available.
Despite the extensive resources analysed, the power to detect predictions across study using 
PRS remained low for antidepressant response, although the power was adequate when we 
investigated common genetic liability with MDD and schizophrenia.  The modest 
pharmacogenetic study sample sizes also precluded other whole-genome-approaches to 
estimate genetic correlation using GCTA or LD score regression (Yang et al., 2011; Bulik-
Sullivan et al., 2015). A sample size ten-times larger would be required to achieve 80% for 
polygenic prediction between studies of antidepressant response.  National registers and 
electronic medical records of large health care organisations could be used to achieve a study 
of this magnitude, but requires substantial resources for selection of appropriate subjects, 
phenotyping, DNA collection, genotyping and analysis.  The power to detect common 
liability with psychiatric disorders was higher, but required the assumption of high genetic 
correlation. 
Other limitations of the study arise from the differences in pharmacogenetic studies in 
characteristics of ascertainment, baseline severity, treatment, assessment of outcome and 
length of follow-up.  We chose to focus on two largest studies (GENDEP, STAR*D) in test 
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PRS for antidepressant response, to avoid adding multiple smaller studies where noise would 
outweigh signal.  In the higher powered analysis assessing genetic component of MDD and 
schizophrenia, we included all available pharmacogenetic studies. Although there were 
substantial diﬀerences in the design of the studies, inclusion criteria were relatively similar 
and it was possible to establish comparable outcome measures. Ethnicity is also a possible 
cause of stratification in GWAS despite correction using ancestry-informative principal 
components. 
We performed a single sub-analysis restricting to participants treated by citalopram or 
escitalopram, since escitalopram is the active isomer of citalopram (N=2308 participants) 
(Svensson and Mansfield, 2004). These analyses also failed to predict improvement of anti-
depressant symptoms or remission. Many further sub-hypotheses could be tested, for 
example, stratifying by sex, symptom dimensions, age, or severity.  Recognising the need to 
balance a larger effect size in one subgroup against the smaller sample size and increased 
correction for multiple testing, we focussed on the key hypotheses (Traylor, Markus and 
Lewis, 2015).
The identification of individual genetic associations with antidepressant treatment response 
has been challenging, with no genome-wide studies identifying replicated signals for 
association (Uher et al., 2010; Garriock et al., 2010; Ising et al., 2009). Since no major, 
single locus variants play a major role in treatment response, building polygenic predictors, 
which capture modest effects at multiple SNPs, may be a feasible alternative.  STAR*D, 
GENDEP and other NEWMEDS studies show a strong polygenic component to the genetic 
architecture of response to antidepressants, with common genetic variation estimated to 
explain 42% of individual differences (SE = 0.180, p = 0.009) (Tansey et al., 2013). With the 
decreasing costs of genotyping, and increasing access to such data, a PRS could form a 
powerful predictor response, and be of clinical value, as already seen in predicting disease 
risk (Chhibber et al., 2014; Chatterjee, Shi and García-Closas, 2016).  Other strategies, such 
as machine learning application to clinical and genetic variables in STAR*D and NEWMEDs 
studies showed some prediction based on both genetic and clinical characteristics, which was 
antidepressant specific (Iniesta et al., 2016). 
We selected here two reasonable polygenic hypotheses that (1) the genetic component of 
antidepressant response from a single study would transfer across studies, and (2) that genetic 
liability for psychiatric disorders would predict response to antidepressants.  Neither of 
hypotheses could be confirmed in the currently available datasets and true polygenic 
component for antidepressant response would require much larger cohorts.  Recent successes 
in uncovering the genetic component of psychiatric disorders are encouraging, but progress in 
uncovering the genetic component to treatment response remains slower.  Expanded cohorts 
will be necessary to uncover the genetic architecture of antidepressant response, an essential 
step if precision medicine in depression is to become attainable.  
12
Acknowledgements
We thank the NIMH for access to data on the STAR*D study. We also thank the authors of 
previous publications in this dataset, and foremost, we thank the patients and their families 
who accepted to be enrolled in the study. Data and biomaterials were obtained from the 
limited access datasets distributed from the NIH-supported ‘‘Sequenced Treatment 
Alternatives to Relieve Depression’’ (STAR*D). The study was supported by NIMH 
Contract No. N01MH90003 to the University of Texas Southwestern Medical Center. The 
ClinicalTrials.gov identifier is NCT00021528.
We thank the University of Muenster, Germany, for having given the possibility of analysing 
their data on the MDD cohort that they collected between 2004 and 2006. 
We also thank the authors of previous publications in these datasets, and foremost, we thank 
the patients who enrolled in these studies.
Funding sources
This work was partially funded by the European Commission Framework 6 grant, EC 
Contract LSHB-CT-2003-503428 and an Innovative Medicine Initiative Joint Undertaking 
(IMI-JU) grant n°115008 of which resources are composed of European Union and the 
European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind 
contribution and financial contribution from the European Union's Seventh Framework 
Programme (FP7/2007-2013). 
This article represents independent research part funded by the National Institute for Health 
Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King’s College London. The views expressed are those of the authors 
and not necessarily those of the NHS, the NIHR or the Department of Health.
The funding source had no role in study design, collection, analysis or interpretation of data, 
in the writing of the report or in the decision to submit the article for publication.
13
References
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition: DSM-5.  American Psychiatric Publishing; 5 edition.
Anon (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 5th edition edition. 
Washington, D.C: American Psychiatric Publishing.
Baune, B.T., Dannlowski, U., Domschke, K., Janssen, D.G.A., Jordan, M.A., Ohrmann, P., Bauer, J., 
Biros, E., Arolt, V., Kugel, H., Baxter, A.G. and Suslow, T. (2010) The interleukin 1 beta 
(IL1B) gene is associated with failure to achieve remission and impaired emotion processing 
in major depression. Biological Psychiatry. 67  (6), pp. 543–549. 
doi:10.1016/j.biopsych.2009.11.004.
Baune, B.T., Hohoff, C., Berger, K., Neumann, A., Mortensen, S., Roehrs, T., Deckert, J., Arolt, V. 
and Domschke, K. (2008) Association of the COMT val158met variant with antidepressant 
treatment response in major depression. Neuropsychopharmacology: Official Publication of 
the American College of Neuropsychopharmacology. 33  (4), pp. 924–932. 
doi:10.1038/sj.npp.1301462.
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J. and Erbaugh, J. (1961) An inventory for measuring 
depression. Archives of General Psychiatry. 4 pp. 561–571.
Biernacka, J.M., Sangkuhl, K., Jenkins, G., Whaley, R.M., Barman, P., Batzler, A., Altman, R.B., 
Arolt, V., Brockmöller, J., Chen, C.H., Domschke, K., Hall-Flavin, D.K., Hong, C.J., Illi, A., 
et al. (2015) The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide 
association study of antidepressant treatment response. Translational Psychiatry. 5 pp. e553. 
doi:10.1038/tp.2015.47.
Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, 
A.L. and Neale, B.M. (2015) LD Score regression distinguishes confounding from 
polygenicity in genome-wide association studies. Nature Genetics. 47  (3), pp. 291–295. 
doi:10.1038/ng.3211.
Chatterjee, N., Shi, J. and García-Closas, M. (2016) Developing and evaluating polygenic risk 
prediction models for stratified disease prevention. Nature Reviews. Genetics. 17  (7), pp. 
392–406. doi:10.1038/nrg.2016.27.
Chhibber, A., Kroetz, D.L., Tantisira, K.G., McGeachie, M., Cheng, C., Plenge, R., Stahl, E., Sadee, 
W., Ritchie, M.D. and Pendergrass, S.A. (2014) Genomic architecture of pharmacological 
efficacy and adverse events. Pharmacogenomics. 15  (16), pp. 2025–2048. 
doi:10.2217/pgs.14.144.
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with 
shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet (London, 
England). 381  (9875), pp. 1371–1379. doi:10.1016/S0140-6736(12)62129-1.
Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee, S.H., Ripke, S., Neale, B.M., 
Faraone, S.V., Purcell, S.M., Perlis, R.H., Mowry, B.J., Thapar, A., Goddard, M.E., Witte, 
J.S., Absher, D., Agartz, I., Akil, H., et al. (2013) Genetic relationship between five 
psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 45  (9), pp. 984–
994. doi:10.1038/ng.2711.
Dudbridge, F. (2013) Power and Predictive Accuracy of Polygenic Risk Scores Naomi R. Wray (ed.). 
PLoS Genetics. 9  (3), pp. e1003348. doi:10.1371/journal.pgen.1003348.
14
Euesden, J., Lewis, C.M. and O’Reilly, P.F. (2015) PRSice: Polygenic Risk Score software. 
Bioinformatics. 31  (9), pp. 1466–1468. doi:10.1093/bioinformatics/btu848.
Fabbri, C., Crisafulli, C., Calabrò, M., Spina, E. and Serretti, A. (2016) Progress and prospects in 
pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism & 
Toxicology. pp. 1–12. doi:10.1080/17425255.2016.1202237.
Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., Reinalda, M.S., 
Slager, S.L., McGrath, P.J. and Hamilton, S.P. (2010) A Genomewide Association Study of 
Citalopram Response in Major Depressive Disorder. Biological Psychiatry. 67  (2), pp. 133–
138. doi:10.1016/j.biopsych.2009.08.029.
Gaynes, B.N., Warden, D., Trivedi, M.H., Wisniewski, S.R., Fava, M. and Rush, A.J. (2009) What 
did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with 
depression. Psychiatric Services (Washington, D.C.). 60  (11), pp. 1439–1445. 
doi:10.1176/ps.2009.60.11.1439.
GENDEP Investigators, MARS Investigators and STAR*D Investigators (2013) Common genetic 
variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three 
genome-wide pharmacogenetic studies. The American Journal of Psychiatry. 170  (2), pp. 
207–217. doi:10.1176/appi.ajp.2012.12020237.
Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, 
prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 
188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. 
Lancet (London, England). 386  (9995), pp. 743–800. doi:10.1016/S0140-6736(15)60692-4.
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. The British Journal 
of Social and Clinical Psychology. 6  (4), pp. 278–296.
Hyde, C.L., Nagle, M.W., Tian, C., Chen, X., Paciga, S.A., Wendland, J.R., Tung, J.Y., Hinds, D.A., 
Perlis, R.H. and Winslow, A.R. (2016) Identification of 15 genetic loci associated with risk of 
major depression in individuals of European descent. Nature Genetics. 48  (9), pp. 1031–
1036. doi:10.1038/ng.3623.
Iniesta, R., Malki, K., Maier, W., Rietschel, M., Mors, O., Hauser, J., Henigsberg, N., Dernovsek, 
M.Z., Souery, D., Stahl, D., Dobson, R., Aitchison, K.J., Farmer, A., Lewis, C.M., et al. 
(2016) Combining clinical variables to optimize prediction of antidepressant treatment 
outcomes. Journal of Psychiatric Research. 78 pp. 94–102. 
doi:10.1016/j.jpsychires.2016.03.016.
Ising, M., Lucae, S., Binder, E.B., Bettecken, T., Uhr, M., Ripke, S., Kohli, M.A., Hennings, J.M., 
Horstmann, S., Kloiber, S., Menke, A., Bondy, B., Rupprecht, R., Domschke, K., et al. (2009) 
A genomewide association study points to multiple loci that predict antidepressant drug 
treatment outcome in depression. Archives of General Psychiatry. 66  (9), pp. 966–975. 
doi:10.1001/archgenpsychiatry.2009.95.
Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, 
E.E., Wang, P.S. and National Comorbidity Survey Replication (2003) The epidemiology of 
major depressive disorder: results from the National Comorbidity Survey Replication (NCS-
R). JAMA. 289  (23), pp. 3095–3105. doi:10.1001/jama.289.23.3095.
Lane, P. (2008) Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and 
MMRM approaches. Pharmaceutical Statistics. 7  (2), pp. 93–106. doi:10.1002/pst.267.
15
Mallinckrodt, C.H., Clark, W.S. and David, S.R. (2001) Accounting for dropout bias using mixed-
effects models. Journal of Biopharmaceutical Statistics. 11  (1–2), pp. 9–21. doi:10.1081/BIP-
100104194.
Montgomery, S.A. and Asberg, M. (1979) A new depression scale designed to be sensitive to change. 
The British Journal of Psychiatry: The Journal of Mental Science. 134 pp. 382–389.
Myung, W., Kim, J., Lim, S.-W., Shim, S., Won, H.-H., Kim, S., Kim, S., Lee, M.-S., Chang, H.S., 
Kim, J.-W., Carroll, B.J. and Kim, D.K. (2015) A genome-wide association study of 
antidepressant response in Koreans. Translational Psychiatry. 5 pp. e633. 
doi:10.1038/tp.2015.127.
Palla, L. and Dudbridge, F. (2015) A Fast Method that Uses Polygenic Scores to Estimate the 
Variance Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting 
a Trait. American Journal of Human Genetics. 97  (2), pp. 250–259. 
doi:10.1016/j.ajhg.2015.06.005.
Perälä, J., Suvisaari, J., Saarni, S.I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-
Henriksson, A., Hintikka, J., Kieseppä, T., Härkänen, T., Koskinen, S. and Lönnqvist, J. 
(2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. 
Archives of General Psychiatry. 64  (1), pp. 19–28. doi:10.1001/archpsyc.64.1.19.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller, J., Sklar, 
P., de Bakker, P.I.W., Daly, M.J. and Sham, P.C. (2007) PLINK: a tool set for whole-genome 
association and population-based linkage analyses. American Journal of Human Genetics. 81  
(3), pp. 559–575. doi:10.1086/519795.
Ripke, S., Neale, B.M., Corvin, A., Walters, J.T.R., Farh, K.-H., Holmans, P.A., Lee, P., Bulik-
Sullivan, B., Collier, D.A., Huang, H., Pers, T.H., Agartz, I., Agerbo, E., Albus, M., et al. 
(2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature. 511  
(7510), pp. 421–427. doi:10.1038/nature13595.
Ripke, S., O’Dushlaine, C., Chambert, K., Moran, J.L., Kähler, A.K., Akterin, S., Bergen, S.E., 
Collins, A.L., Crowley, J.J., Fromer, M., Kim, Y., Lee, S.H., Magnusson, P.K.E., Sanchez, 
N., et al. (2013a) Genome-wide association analysis identifies 13 new risk loci for 
schizophrenia. Nature Genetics. 45  (10), pp. 1150–1159. doi:10.1038/ng.2742.
Ripke, S., Wray, N.R., Lewis, C.M., Hamilton, S.P., Weissman, M.M., Breen, G., Byrne, E.M., 
Blackwood, D.H.R., Boomsma, D.I., Cichon, S., Heath, A.C., Holsboer, F., Lucae, S., 
Madden, P.A.F., et al. (2013b) A mega-analysis of genome-wide association studies for major 
depressive disorder. Molecular Psychiatry. 18  (4), pp. 497–511. doi:10.1038/mp.2012.21.
Sasayama, D., Hiraishi, A., Tatsumi, M., Kamijima, K., Ikeda, M., Umene-Nakano, W., Yoshimura, 
R., Nakamura, J., Iwata, N. and Kunugi, H. (2013) Possible association of CUX1 gene 
polymorphisms with antidepressant response in major depressive disorder. The 
Pharmacogenomics Journal. 13  (4), pp. 354–358. doi:10.1038/tpj.2012.18.
Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., 
Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Zohar, J. and Mendlewicz, J. 
(2011) Switching antidepressant class does not improve response or remission in treatment-
resistant depression. Journal of Clinical Psychopharmacology. 31  (4), pp. 512–516. 
doi:10.1097/JCP.0b013e3182228619.
16
Steimer, W., Müller, B., Leucht, S. and Kissling, W. (2001) Pharmacogenetics: a new diagnostic tool 
in the management of antidepressive drug therapy. Clinica Chimica Acta. 308  (1–2), pp. 33–
41. doi:10.1016/S0009-8981(01)00423-5.
Streiner, D.L. (2002) Breaking up is hard to do: the heartbreak of dichotomizing continuous data. 
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 47  (3), pp. 262–266.
Svensson, S. and Mansfield, P.R. (2004) Escitalopram: superior to citalopram or a chiral chimera? 
Psychotherapy and Psychosomatics. 73  (1), pp. 10–16. doi:10.1159/000074435.
Tansey, K.E., Guipponi, M., Domenici, E., Lewis, G., Malafosse, A., O’Donovan, M., Wendland, 
J.R., Lewis, C.M., McGuffin, P. and Uher, R. (2014) Genetic susceptibility for bipolar 
disorder and response to antidepressants in major depressive disorder. American Journal of 
Medical Genetics Part B: Neuropsychiatric Genetics. 165  (1), pp. 77–83. 
doi:10.1002/ajmg.b.32210.
Tansey, K.E., Guipponi, M., Hu, X., Domenici, E., Lewis, G., Malafosse, A., Wendland, J.R., Lewis, 
C.M., McGuffin, P. and Uher, R. (2013) Contribution of Common Genetic Variants to 
Antidepressant Response. Biological Psychiatry. 73  (7), pp. 679–682. 
doi:10.1016/j.biopsych.2012.10.030.
Tansey, K.E., Guipponi, M., Perroud, N., Bondolfi, G., Domenici, E., Evans, D., Hall, S.K., Hauser, 
J., Henigsberg, N., Hu, X., Jerman, B., Maier, W., Mors, O., O’Donovan, M., et al. (2012) 
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major 
depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. 
PLoS medicine. 9  (10), pp. e1001326. doi:10.1371/journal.pmed.1001326.
The WHO World Mental Health Survey Consortium (2004) PRevalence, severity, and unmet need for 
treatment of mental disorders in the world health organization world mental health surveys. 
JAMA. 291  (21), pp. 2581–2590. doi:10.1001/jama.291.21.2581.
Traylor, M., Markus, H. and Lewis, C.M. (2015) Homogeneous case subgroups increase power in 
genetic association studies. European journal of human genetics: EJHG. 23  (6), pp. 863–869. 
doi:10.1038/ejhg.2014.194.
Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., 
Howland, R.H., Lebowitz, B., McGrath, P.J. and others (2006) Evaluation of outcomes with 
citalopram for depression using measurement-based care in STAR* D: implications for 
clinical practice. American journal of Psychiatry [online]. Available from: 
http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.163.1.28 [Accessed 10 May 2016].
Uher, R., Farmer, A., Maier, W., Rietschel, M., Hauser, J., Marusic, A., Mors, O., Elkin, A., 
Williamson, R.J., Schmael, C., Henigsberg, N., Perez, J., Mendlewicz, J., Janzing, J.G.E., et 
al. (2008) Measuring depression: comparison and integration of three scales in the GENDEP 
study. Psychological Medicine [online]. 38  (2), . Available from: 
http://www.journals.cambridge.org/abstract_S0033291707001730doi:10.1017/S00332917070
01730 [Accessed 7 July 2016].
Uher, R., Maier, W., Hauser, J., Marusic, A., Schmael, C., Mors, O., Henigsberg, N., Souery, D., 
Placentino, A., Rietschel, M., Zobel, A., Dmitrzak-Weglarz, M., Petrovic, A., Jorgensen, L., 
et al. (2009) Differential efficacy of escitalopram and nortriptyline on dimensional measures 
of depression. The British Journal of Psychiatry: The Journal of Mental Science. 194  (3), pp. 
252–259. doi:10.1192/bjp.bp.108.057554.
17
Uher, R., Perroud, N., Ng, M.Y., Hauser, J., Henigsberg, N., Maier, W., Mors, O., Placentino, A., 
Rietschel, M., Souery, D. and others (2010) Genome-wide pharmacogenetics of 
antidepressant response in the GENDEP project. American Journal of Psychiatry [online]. 
Available from: http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2009.09070932 
[Accessed 12 February 2016].
World Health Organization (1993) The ICD-10 Classification of Mental and Behavioural Disorders: 
Diagnostic Criteria for Research.  (no place) World Health Organisation (1 Jan. 1993).
Yang, J., Lee, S.H., Goddard, M.E. and Visscher, P.M. (2011) GCTA: a tool for genome-wide 
complex trait analysis. American Journal of Human Genetics. 88  (1), pp. 76–82. 
doi:10.1016/j.ajhg.2010.11.011.
Figure 1:  Study design, capturing (1) prediction of improvement and remission using large 
antidepressant response trials as discovery studies, and (2) prediction from psychiatric disorder 
PRS, into all antidepressant studies. Arrows indicate PRS from discovery to test data sets.  
PGC=Psychiatric Genomics Consortium. 
Figure 2:  Meta-analysis of PRS effect sizes (β) in seven pharmacogenetic studies for (1) MDD and 
(2) schizophrenia PRS.  Labels show p-values for meta-analyses at each p threshold.
1. MDD
2. Schizophrenia
Table 1 Pharmacogenetic study characteristics. MADRS; Montgomery-Åsberg Depression Rating Scale. QIDS-C16; Quick Inventory of Depressive Symptomatology-Clinician 
Rated. BDI; Beck Depression Inventory. HAMD-17; Hamilton Rating Scale for Depression (17 items). HAMD-21; Hamilton Rating Scale for Depression (21 items). SSRIs; 
selective serotonin reuptake inhibitors. SNRIs; serotonin and noradrenaline reuptake inhibitors. 
STAR*D GENDEP GENPOD Pfizer GSK GODS Muenster
Sample characteristics
Study design Trial Trial Trial Trial Trial Trial Naturalistic
N 1409 736 473 307 130 70 621
Scale for outcome assessment QIDS-C16 MADRS BDI HAMD-17 HAMD-17 MADRS HAMD-21
Time of end point assessment 12 weeks 12 weeks 12 weeks 12 weeks 12 weeks 12 weeks 6 weeks
Criteria for remission QIDS-C16 ≤ 5 HAMD-17 ≤ 7 BDI < 10 HAMD-17 ≤ 7 HAMD-17 ≤ 7 MADRS ≤ 8 HAMD-21 ≤ 7
Treatment citalopram
escitalopram     
nortriptyline
citalopram 
reboxetine
sertraline    
fluoxetine   
paroxetine
escitalopram paroxetine
SSRIs, SNRIs, 
others
Genotyping platform Affymetrix   500K, 
Illumina Infinium 
Exome-24 v1.0
Illumina Human610,  
Infinium Exome-24 v1.0 
Illumina 660W Illumina 660W Illumina 660W Illumina 660W  Infinium 
PsychArray-24
Imputation panel Haplotype Reference 
Consortium
Haplotype Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Clinical characteristics
% Female 59.9 62 69.2 67.2 54.5 53.4 43.1
Age at onset 27.3 (SD 14.2) 32.0 (SD 10.6) 39.4 (SD 12.5) 43.3 (SD 13.1) 36.4 (SD 11.9) 37.1 (SD 10.3) 39.0 (SD 15.0)
MDD severity
Moderate to Severe Moderate to Severe
Moderate to 
Severe
Moderate to Severe
Moderate to 
Severe
Severe Mild to Severe
Baseline measure
HAMD-17 HAMD-17 BDI HAMD-17 HAMD-17 MADRS HAMD-21
Score 22.4 (SD 4.9) 21.9 (SD 5.2) 33.4 (SD 9.7) 23.5 (SD 3.4) 23.0 (SD 3.1) 31.8 (SD 4.7) 22.3 (SD 7.3)
Achieved remission 602 (42.7%) 322 (44%) 171 (36%) 100 (32%) 56 (43%) 17 (24%) 279 (45%)

Table 2:  Prediction of improvement in depression symptoms and remission after 12 weeks of 
antidepressant treatment. Results are shown for the PT threshold attaining the lowest p-value. R2; 
Proportion of variance explained.
Discovery 
sample
Target 
sample
Phenotype PT
No. of 
SNPs
R2 P-value
Whole sample
Improvement 0.001 1422 0.00079 0.280
GENDEP STAR*D
Remission 0.0001 934 0.00044 0.024
Improvement 0.05 39471 0.00173 0.237
STAR*D GENDEP
Remission 0.5 214280 0.00212 0.234
Analyses including only citalopram/escitalopram treated 
subjects
Improvement 0.001 1429 0.00056 0.361
GENDEP STAR*D
Remission 0.001 827 0.00199 0.130
Improvement 0.05 39471 0.00214 0.313
STAR*D GENDEP
Remission 0.5 214280 0.00335 0.255
